Ascenta Therapeutics Inc. and The Leukemia & Lymphoma Society Announce Agreement to Develop AT-406 for Leukemia

MALVERN, Pa. & WHITE PLAINS, N.Y.--(BUSINESS WIRE)--Ascenta Therapeutics, Inc. and The Leukemia & Lymphoma Society (LLS) today entered into an agreement whereby the LLS will support clinical development of Ascenta’s oral small molecule inhibitor of IAPs (inhibitor of apoptosis proteins), AT-406, for patients with acute myeloid leukemia (AML).

MORE ON THIS TOPIC